<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01448824</url>
  </required_header>
  <id_info>
    <org_study_id>14460</org_study_id>
    <secondary_id>I1V-MC-EIAL</secondary_id>
    <nct_id>NCT01448824</nct_id>
  </id_info>
  <brief_title>A Study of LY2484595 on Pharmacokinetics in Healthy Participants</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Safety and Tolerability of LY2484595 SDSD-PG Tablets and the Effect of CYP3A Inhibition by Ketoconazole on the Pharmacokinetics of LY2484595 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-part study. Part 1 is to determine the safety and tolerability in healthy
      participants of increasing daily doses of LY2484595 for 14 days to achieve a blood level of
      LY2484595 much higher than what is needed for therapy. The amount of study drug that reaches
      the bloodstream and the time it takes for the body to get rid of it will be determined. The
      effect of the study drug on factors in the blood related to cholesterol will be measured.

      Part 2 is to determine how ketoconazole affects how much of the study drug, LY2484595, gets
      into the bloodstream and how long it takes to get rid of it. Information about any side
      effects that may occur will also be collected.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a 2-part, multiple ascending dose (MAD) and drug drug interaction (DDI) study
      to evaluate the safety and tolerability and the effect of cytochrome P450 (CYP) 3A inhibition
      by ketoconazole on the pharmacokinetics of LY2484595 in healthy participants.

      In the MAD portion (Part 1) of this study, participants in 4 cohorts (Cohorts A through D)
      will be randomized to receive either LY2484595 (5 ascending dose levels [100 to 1800 mg]) or
      placebo. Cohorts will have staggered starts ≥7 days from the previous cohort to allow for
      review of safety and tolerability. The total duration of Part 1 is approximately 13 weeks
      including screening.

      Participants in Cohort A will participate in 2 periods separated by a washout period lasting
      ≥14 days. During Period 1, participants will receive the starting dose of LY2484595 (100 mg)
      or placebo once daily (QD) for 14 consecutive days. During Period 2, participants will
      receive the highest dose of LY2484595 (1800 mg) or placebo QD for 14 consecutive days.
      Participants will complete a follow-up visit ≥14 days after the last dose of study drug.

      Participants in Cohorts B, C, and D will receive LY2484595 (300, 600, and 1200 mg LY2484595,
      respectively) or placebo QD for 14 consecutive days followed by a follow-up visit ≥14 days
      after last dose of study drug.

      The DDI portion of this study (Part 2) will be open label and consist of 2 periods. The total
      duration of Part 2 is approximately 10 weeks. LY2484595 (100 mg) will be administered on Day
      1 of Period 1 and on Day 5 of Period 2. In Period 2, ketoconazole (400 mg) will be
      administered QD for 14 consecutive days (13 days alone [Days 1 through 4 and 6 through 14] +
      1 day with LY2484595 [Day 5]). There will be a ≥14-day washout period between dosing during
      Period 1 and Period 2. Participants will return for a follow-up visit ≥14 days after last
      dose of study drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of Participants With 1 or More Adverse Events (AEs) or Any Serious AEs</measure>
    <time_frame>Part 1: Baseline through ≥14 days after last dose of study drug (≥Day 28)</time_frame>
    <description>The number of participants with 1 or more AEs is summarized cumulatively. In addition, the number of participants with any serious AEs is summarized cumulatively. A serious AE is defined as an event that results in death, initial or prolonged hospitalization, is life-threatening, leads to persistent or significant disability/incapacity, is associated with congenital anomaly/birth defect, or is considered significant by the investigator for any other reason. A summary of serious and other non-serious AEs regardless of causality is located in the Reported Adverse Events module.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of LY2484595</measure>
    <time_frame>Part 2, Period 1, Day 1 through Day 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168 Hours Post Dose; Period 2, Day 5 through Day 15: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240 Hours Post Dose</time_frame>
    <description>The geometric least squares (LS) means for the maximum observed plasma concentration (Cmax) of LY2484595 following administration of LY2484595 alone and with ketoconazole are reported. Least squares means were calculated from an analysis of variance (ANOVA) model with a fixed effect for treatment and a random effect for participant. The LS means for each treatment and the 90% confidence intervals (CI) for the difference in means were back transformed from the log scale to provide estimates of the geometric means and 90% CIs for the ratio of the geometric means (LY2484595 coadministered with ketoconazole and LY2484595 alone).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Time of Maximum Observed Plasma Concentration (Tmax) of LY2484595</measure>
    <time_frame>Part 2, Period 1, Day 1 through Day 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168 Hours Post Dose; Period 2, Day 5 through Day 15: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240 Hours Post Dose</time_frame>
    <description>The median times to maximum observed plasma concentration (Tmax) of LY2484595 following administration of LY2484595 alone and with ketoconazole are reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration-time Curve (AUC) of LY2484595</measure>
    <time_frame>Part 2, Period 1, Day 1 through Day 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168 Hours Post Dose; Period 2, Day 5 through Day 15: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240 Hours Post Dose</time_frame>
    <description>The geometric least squares (LS) means of area under the concentration-time curve (AUC) from time zero extrapolated to infinity (AUC0-∞) of LY2484595 following administration of LY2484595 alone and with ketoconazole are reported. Least squares means were calculated from an analysis of variance (ANOVA) model with a fixed effect for treatment and a random effect for participant. The LS means for each treatment and the 90% confidence intervals (CI) for the difference in means were back transformed from the log scale to provide estimates of the geometric means and 90% CIs for the ratio of the geometric means (LY2484595 coadministered with ketoconazole and LY2484595 alone).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Change From Baseline to Day 21 in Cholesteryl Ester Transfer Protein (CETP) Activity</measure>
    <time_frame>Day 1 (Baseline) and Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Change From Baseline to Day 21 in High-density Lipoprotein Cholesterol (HDL-C), Low-density Lipoprotein Cholesterol (LDL-C), and Triglycerides (TG)</measure>
    <time_frame>Day 1 (Baseline) and Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of LY2484595</measure>
    <time_frame>Part 1, Periods 1 and 2, Day 1: Predose, 1, 2, 3, 4, 6, 8, 12, and 24 Hours Postdose; Day 14 through Day 21: Predose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 168 Hours Post Dose</time_frame>
    <description>The maximum observed plasma concentrations (Cmax) of LY2484595 after a single dose and after once daily (QD) dosing for 14 consecutive days are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time of Maximum Observed Plasma Concentration (Tmax) of LY2484595</measure>
    <time_frame>Part 1, Periods 1 and 2, Day 1: Predose, 1, 2, 3, 4, 6, 8, 12, and 24 Hours Postdose; Day 14 through Day 21: Predose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 168 Hours Post Dose</time_frame>
    <description>The times of maximum observed plasma concentrations (tmax) of LY2484595 after a single dose and after once daily (QD) dosing for 14 consecutive days are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration-time Curve (AUC) of LY2484595</measure>
    <time_frame>Part 1, Periods 1 and 2, Day 1: Predose, 1, 2, 3, 4, 6, 8, 12, and 24 Hours Postdose; Day 14 through Day 21: Predose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 168 Hours Post Dose</time_frame>
    <description>Exposure to LY2484595 in terms of the area under the concentration-time curves (AUC) after a single dose and after once daily (QD) dosing for 14 consecutive days are reported.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Part 1 (Cohort A): 100 mg, 1800 mg LY2484595, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants will receive either 100 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14 of Period 1.
Washout period lasting ≥14 days.
Period 2: Participants will receive either 1800 mg LY2484595 tablets or placebo tablets QD by mouth on Days 1 through 14 of Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 (Cohort B): 300 mg LY2484595, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive either 300 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 (Cohort C): 600 mg LY2484595, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive either 600 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 (Cohort D): 1200 mg LY2484595, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive either 1200 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (Cohort E): 100 mg LY2484595 ± 400 mg Ketoconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Participants will receive 100 milligrams (mg) LY2484595 tablet by mouth on Day 1 of Period 1.
Washout period lasting ≥14 days.
Period 2: Participants will receive 400 mg ketoconazole tablets once daily (QD) by mouth on Days 1 through 14 of Period 2. Participants will receive 100 mg LY2484595 tablet by mouth on Day 5 of Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2484595</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part 1 (Cohort A): 100 mg, 1800 mg LY2484595, Placebo</arm_group_label>
    <arm_group_label>Part 1 (Cohort B): 300 mg LY2484595, Placebo</arm_group_label>
    <arm_group_label>Part 1 (Cohort C): 600 mg LY2484595, Placebo</arm_group_label>
    <arm_group_label>Part 1 (Cohort D): 1200 mg LY2484595, Placebo</arm_group_label>
    <arm_group_label>Part 2 (Cohort E): 100 mg LY2484595 ± 400 mg Ketoconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part 1 (Cohort A): 100 mg, 1800 mg LY2484595, Placebo</arm_group_label>
    <arm_group_label>Part 1 (Cohort B): 300 mg LY2484595, Placebo</arm_group_label>
    <arm_group_label>Part 1 (Cohort C): 600 mg LY2484595, Placebo</arm_group_label>
    <arm_group_label>Part 1 (Cohort D): 1200 mg LY2484595, Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part 2 (Cohort E): 100 mg LY2484595 ± 400 mg Ketoconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are overtly healthy males or females, as determined by medical history and physical
             examination

          -  Female participants and women not of childbearing potential due to surgical
             sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation) or menopause.
             Postmenopausal is defined as women age &gt;45 with an intact uterus who have not taken
             hormones or oral contraceptives within the last year, and who have had either
             cessation of menses greater than or equal to 1 year or 6 to 12 months of spontaneous
             amenorrhea with follicle-stimulating hormone (FSH) &gt;40 milli-international units per
             milliliter (40 international units per liter [IU/L]).

          -  Have a body mass index (BMI) between 18 to 32 kilograms per square meter (kg/m^2),
             inclusive

          -  Have clinical laboratory test results within normal reference range for the population
             or investigator site, or results with acceptable deviations that are judged to be not
             clinically significant by the investigator

          -  Have venous access sufficient to allow for blood sampling

          -  Are reliable and willing to make themselves available for the duration of the study
             and are willing to follow study procedures

          -  Have given written informed consent approved by Lilly and the institutional review
             board (IRB) governing the site

        Exclusion Criteria:

          -  Are currently enrolled in, have completed or discontinued within the last 30 days from
             a clinical trial involving an investigational product, or are concurrently enrolled in
             any other type of medical research judged not to be scientifically or medically
             compatible with this study

          -  Have known allergies to LY2484595 or related compounds, contraindications to
             ketoconazole or related compounds, or allergies to any components of the formulations

          -  Are persons who have previously completed or withdrawn from this study or any other
             study investigating LY2484595 and have previously received the investigational product

          -  Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the
             investigator, increases the risks associated with participating in the study and/or
             poses difficulties in the interpretation of eventual changes occurring during the
             study

          -  Have systolic blood pressure of &gt;140 millimeters of mercury (mmHg) or diastolic blood
             pressure of &gt;90 mmHg

          -  Have a history or presence of cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs; of
             constituting a risk when taking the study medication; or of interfering with the
             interpretation of data

          -  Regularly use known drugs of abuse and/or show positive findings on urinary drug
             screening

          -  Show evidence of human immunodeficiency virus infection (HIV) and/or positive human
             HIV antibodies

          -  Show evidence of hepatitis C and/or positive hepatitis C antibody

          -  Show evidence of hepatitis B and/or positive hepatitis B surface antigen

          -  Are women with a positive pregnancy test or women who are lactating

          -  Have used or intend to use over-the-counter or prescription medication within 14 days
             prior to dosing unless deemed acceptable by the investigator and sponsor's medical
             monitor

          -  Use of any drugs or substances that are known to be an inducer or inhibitor of
             cytochrome p450 3A4 (CYP3A4) (for example, St. John's wort) within 30 days prior to
             first dose of study drug

          -  Have donated blood of more than 500 milliliters (mL) within 30 days prior to first
             dose of study drug

          -  Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14
             units per week (females) or are unwilling to stop alcohol consumption for the duration
             of the study (1 unit equals 12 ounces [oz] or 360 mL of beer; 5 oz or 150 mL of wine;
             1.5 oz or 45 mL of distilled spirits)

          -  Consume 5 or more cups of coffee (or other beverages of comparable caffeine content)
             per day, on a habitual basis, or any subjects unwilling to adhere to study caffeine
             restriction

          -  Have a daily use of greater than or equal to 5 tobacco- or nicotine-containing
             products (including but not limited to cigarettes, pipes, cigars, chewing tobacco,
             nicotine patches, nicotine lozenges, or nicotine gum) and are unwilling to refrain
             from using any tobacco- or nicotine-containing products within 7 days prior to first
             dose through the follow-up visit

          -  Have consumed grapefruit, grapefruit juice, Seville orange, Seville orange juice, or
             starfruit or products that contain these fruits within 7 days prior to first dose and
             during the study

          -  Unwilling to refrain from daily consumption of black licorice containing glycyrrhizic
             acid (that is, real licorice)

          -  In the opinion of the investigator or sponsor, are unsuitable for inclusion in the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri, 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>October 6, 2011</study_first_submitted>
  <study_first_submitted_qc>October 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2011</study_first_posted>
  <results_first_submitted>February 18, 2018</results_first_submitted>
  <results_first_submitted_qc>March 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 2, 2019</results_first_posted>
  <last_update_submitted>March 29, 2019</last_update_submitted>
  <last_update_submitted_qc>March 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low High-density Lipoprotein (HDL)</keyword>
  <keyword>Cholesterol (HDL-C)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Evacetrapib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This was a 2-part study, multiple ascending dose (MAD) and drug drug interaction (DDI). Participants were randomized to (Part 1) to 4 cohorts (Cohorts A through D) and randomized to receive either LY2484595 (5 ascending dose levels) or placebo. Cohort A consisted of 2 periods separated by a washout period of 14 days. DDI had 2 periods.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1 Cohort A Sequence 1</title>
          <description>Period 1:
LY2484595: 100 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14 of Period 1.
Washout period lasting ≥14 days.
Period 2:
LY2484595: 1800 mg, tablets, oral administration, QD on Days 1 through 14 of Period 2.</description>
        </group>
        <group group_id="P2">
          <title>Part 1 Cohort A Sequence 2</title>
          <description>Period 1:
Placebo: dose-matched tablets, oral administration, once daily (QD) on Days 1 through 14 of Period 1.
Washout period lasting ≥ 14 days
Period 2:
LY2484595: 1800 mg, tablets, oral administration, QD on Days 1 through 14 of Period 2.</description>
        </group>
        <group group_id="P3">
          <title>Part 1 Cohort A Sequence 3</title>
          <description>Period 1:
LY2484595: 100 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14 of Period 1
Washout period lasting ≥14 days
Period 2:
Placebo: tablets, oral administration, QD on Days 1 through 14 of Period 2</description>
        </group>
        <group group_id="P4">
          <title>Part 1 (Cohorts B Through D): Placebo</title>
          <description>Placebo: tablets, oral administration, once daily (QD) on Days 1 through 14.</description>
        </group>
        <group group_id="P5">
          <title>Part 1 Cohort B</title>
          <description>LY2484595: 300 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14.</description>
        </group>
        <group group_id="P6">
          <title>Part 1 Cohort C</title>
          <description>LY2484595: 600 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14.</description>
        </group>
        <group group_id="P7">
          <title>Part 1 Cohort D</title>
          <description>LY2484595: 1200 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14.</description>
        </group>
        <group group_id="P8">
          <title>Part 2 Cohort E</title>
          <description>Period 1:
LY2484595: 100 milligrams (mg), tablet, oral administration, single dose on Day 1 of Period 1.
Washout period lasting ≥ 14 days
Period 2:
Ketoconazole: 400 mg, tablet, oral administration, once daily (QD) on Days 1 through 14 of Period 2.
LY2484595: 100 mg, tablet, oral administration, single dose on Day 5 of Period 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1 Period 1: Multiple Ascending Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="11"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 1: Washout Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0">Participants in Part 1 Cohorts B through D participated in Period 1 only.</participants>
                <participants group_id="P5" count="0">Participants in Part 1 Cohort B participated in Period 1 only.</participants>
                <participants group_id="P6" count="0">Participants in Part 1 Cohort C participated in Period 1 only.</participants>
                <participants group_id="P7" count="0">Participants in Part 1 Cohort D participated in Period 1 only.</participants>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 1 Period 2: Multiple Ascending Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0">Participants in Part 1 Cohorts B through D participated in Period 1 only.</participants>
                <participants group_id="P5" count="0">Participants in Part 1 Cohort B participated in Period 1 only.</participants>
                <participants group_id="P6" count="0">Participants in Part 1 Cohort C participated in Period 1 only.</participants>
                <participants group_id="P7" count="0">Participants in Part 1 Cohort D participated in Period 1 only.</participants>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2 Period 1: Drug-drug Interaction</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 2: Washout Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2 Period 2: Drug-drug Interaction</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Dosing on Day 5</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Part 1 (Cohort A) Sequence 1</title>
          <description>Participants received 100 milligrams (mg) LY2484595 (tablets, oral administration) QD on Days 1 through 14. Then, received 1800 mg LY2484595 QD on Days 1 through 14 period 2.</description>
        </group>
        <group group_id="B2">
          <title>Part 1 (Cohort A) Sequence 2</title>
          <description>Placebo: tablets, oral administration, once daily (QD) on Days 1 through 14 of Period 1 and 1800 mg LY2484595 on Days 1 through 14 of Period 2).</description>
        </group>
        <group group_id="B3">
          <title>Part 1 (Cohort A) Sequence 3</title>
          <description>Participants received 100 mg LY2484595 (tablets, oral administration) once daily (QD) on Days 1 through 14. Then, received placebo QD on Days 1 through 14 period 2.</description>
        </group>
        <group group_id="B4">
          <title>Part 1 (Cohort B Through D) Placebo</title>
          <description>Placebo: tablets, oral administration, once daily (QD) on Days 1 through 14.</description>
        </group>
        <group group_id="B5">
          <title>Part 1 (Cohort B)</title>
          <description>Participants received 300 mg LY2484595 (tablets, oral administration) QD on Days 1 through 14.</description>
        </group>
        <group group_id="B6">
          <title>Part 1 (Cohort C)</title>
          <description>Participants received 600 mg LY2484595 (tablets, oral administration) QD on Days 1 through 14.</description>
        </group>
        <group group_id="B7">
          <title>Part 1 (Cohort D)</title>
          <description>Participants received 1200 mg LY2484595 (tablets, oral administration) QD on Days 1 through 14.</description>
        </group>
        <group group_id="B8">
          <title>Part 2 (Cohort E)</title>
          <description>Participants received 100 mg LY2484595 (tablet, oral administration) as a single dose on Day 1 of Period 1. After a washout period lasting ≥14 days, participants received 400 mg ketoconazole (tablet, oral administration, QD) on Days 1 through 4 of Period 2, 400 mg ketoconazole (tablet, oral administration) and 100 mg LY2484595 (tablet, oral administration) on Day 5 of Period 2, and 400 mg ketoconazole (tablet, oral administration, QD) on Days 6 through 14 of Period 2.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="16"/>
            <count group_id="B6" value="12"/>
            <count group_id="B7" value="12"/>
            <count group_id="B8" value="12"/>
            <count group_id="B9" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.4" spread="11.6"/>
                    <measurement group_id="B2" value="31.3" spread="3.9"/>
                    <measurement group_id="B3" value="41.8" spread="7.4"/>
                    <measurement group_id="B4" value="39.4" spread="13.7"/>
                    <measurement group_id="B5" value="41.1" spread="14.3"/>
                    <measurement group_id="B6" value="39.1" spread="10.7"/>
                    <measurement group_id="B7" value="45.8" spread="11.0"/>
                    <measurement group_id="B8" value="36.6" spread="7.9"/>
                    <measurement group_id="B9" value="39.8" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With 1 or More Adverse Events (AEs) or Any Serious AEs</title>
        <description>The number of participants with 1 or more AEs is summarized cumulatively. In addition, the number of participants with any serious AEs is summarized cumulatively. A serious AE is defined as an event that results in death, initial or prolonged hospitalization, is life-threatening, leads to persistent or significant disability/incapacity, is associated with congenital anomaly/birth defect, or is considered significant by the investigator for any other reason. A summary of serious and other non-serious AEs regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>Part 1: Baseline through ≥14 days after last dose of study drug (≥Day 28)</time_frame>
        <population>All participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 (Cohorts A Through D): Placebo</title>
            <description>Placebo: tablets, oral administration, once daily (QD) on Days 1 through 14 of Period 1 (all cohorts) and Days 1 through 14 of Period 2 (Cohort A only)</description>
          </group>
          <group group_id="O2">
            <title>Part 1, Period 1 (Cohort A): 100 mg LY2484595</title>
            <description>LY2484595: 100 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14 of Period 1</description>
          </group>
          <group group_id="O3">
            <title>Part 1 (Cohort B): 300 mg LY2484595</title>
            <description>LY2484595: 300 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14</description>
          </group>
          <group group_id="O4">
            <title>Part 1 (Cohort C): 600 mg LY2484595</title>
            <description>LY2484595: 600 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14</description>
          </group>
          <group group_id="O5">
            <title>Part 1 (Cohort D): 1200 mg LY2484595</title>
            <description>LY2484595: 1200 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14</description>
          </group>
          <group group_id="O6">
            <title>Part 1, Period 2 (Cohort A): 1800 mg LY2484595</title>
            <description>LY2484595: 1800 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14 of Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With 1 or More Adverse Events (AEs) or Any Serious AEs</title>
          <description>The number of participants with 1 or more AEs is summarized cumulatively. In addition, the number of participants with any serious AEs is summarized cumulatively. A serious AE is defined as an event that results in death, initial or prolonged hospitalization, is life-threatening, leads to persistent or significant disability/incapacity, is associated with congenital anomaly/birth defect, or is considered significant by the investigator for any other reason. A summary of serious and other non-serious AEs regardless of causality is located in the Reported Adverse Events module.</description>
          <population>All participants who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of LY2484595</title>
        <description>The geometric least squares (LS) means for the maximum observed plasma concentration (Cmax) of LY2484595 following administration of LY2484595 alone and with ketoconazole are reported. Least squares means were calculated from an analysis of variance (ANOVA) model with a fixed effect for treatment and a random effect for participant. The LS means for each treatment and the 90% confidence intervals (CI) for the difference in means were back transformed from the log scale to provide estimates of the geometric means and 90% CIs for the ratio of the geometric means (LY2484595 coadministered with ketoconazole and LY2484595 alone).</description>
        <time_frame>Part 2, Period 1, Day 1 through Day 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168 Hours Post Dose; Period 2, Day 5 through Day 15: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240 Hours Post Dose</time_frame>
        <population>Participants who received at least 1 dose of LY2484595 and had evaluable LY2484595 concentration data.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 1: 100 mg LY2484595</title>
            <description>Period 1:
LY2484595: 100 milligrams (mg), tablet, oral administration, single dose on Day 1 of Period 1
Washout period lasting ≥ 14 days
Period 2:
Ketoconazole: 400 mg, tablet, oral administration, once daily (QD) on Days 1 through 14 of Period 2
LY2484595: 100 mg, tablet, oral administration, single dose on Day 5 of Period 2</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Period 2: 100 mg LY2484595 + 400 mg Ketoconazole</title>
            <description>Period 1:
LY2484595: 100 milligrams (mg), tablet, oral administration, single dose on Day 1 of Period 1
Washout period lasting ≥ 14 days
Period 2:
Ketoconazole: 400 mg, tablet, oral administration, once daily (QD) on Days 1 through 14 of Period 2
LY2484595: 100 mg, tablet, oral administration, single dose on Day 5 of Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of LY2484595</title>
          <description>The geometric least squares (LS) means for the maximum observed plasma concentration (Cmax) of LY2484595 following administration of LY2484595 alone and with ketoconazole are reported. Least squares means were calculated from an analysis of variance (ANOVA) model with a fixed effect for treatment and a random effect for participant. The LS means for each treatment and the 90% confidence intervals (CI) for the difference in means were back transformed from the log scale to provide estimates of the geometric means and 90% CIs for the ratio of the geometric means (LY2484595 coadministered with ketoconazole and LY2484595 alone).</description>
          <population>Participants who received at least 1 dose of LY2484595 and had evaluable LY2484595 concentration data.</population>
          <units>Nanograms per milliliter (ng/mL)</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="331.83" lower_limit="236.06" upper_limit="466.45"/>
                    <measurement group_id="O2" value="643.99" lower_limit="448.78" upper_limit="924.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Up to 12 participants were enrolled in order for 8 to complete the study. The estimated variability in area under the concentration-time curve (AUC) was 20% coefficient of variation following a single dose of 100 mg LY2484595. Assuming that 70% of the total variability is contributed by intra-participant variability, a sample size of 8 participants provides a precision of ~15% for the geometric means ratio in AUC and Cmax of LY2484595 + ketoconazole to LY2484595 alone in log scale.</non_inferiority_desc>
            <param_type>Ratio of Geometric LS Means</param_type>
            <param_value>1.94</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.39</ci_lower_limit>
            <ci_upper_limit>2.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Time of Maximum Observed Plasma Concentration (Tmax) of LY2484595</title>
        <description>The median times to maximum observed plasma concentration (Tmax) of LY2484595 following administration of LY2484595 alone and with ketoconazole are reported.</description>
        <time_frame>Part 2, Period 1, Day 1 through Day 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168 Hours Post Dose; Period 2, Day 5 through Day 15: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240 Hours Post Dose</time_frame>
        <population>Participants who received at least 1 dose of LY2484595 and had evaluable LY2484595 concentration data.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 1: 100 mg LY2484595</title>
            <description>Period 1:
LY2484595: 100 milligrams (mg), tablet, oral administration, single dose on Day 1 of Period 1
Washout period lasting ≥ 14 days
Period 2:
Ketoconazole: 400 mg, tablet, oral administration, once daily (QD) on Days 1 through 14 of Period 2.
LY2484595: 100 mg, tablet, oral administration, single dose on Day 5 of Period 2</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Period 2: 100 mg LY2484595 + 400 mg Ketoconazole</title>
            <description>Period 1:
LY2484595: 100 milligrams (mg), tablet, oral administration, single dose on Day 1 of Period 1
Washout period lasting ≥ 14 days
Period 2:
Ketoconazole: 400 mg, tablet, oral administration, once daily (QD) on Days 1 through 14 of Period 2.
LY2484595: 100 mg, tablet, oral administration, single dose on Day 5 of Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Time of Maximum Observed Plasma Concentration (Tmax) of LY2484595</title>
          <description>The median times to maximum observed plasma concentration (Tmax) of LY2484595 following administration of LY2484595 alone and with ketoconazole are reported.</description>
          <population>Participants who received at least 1 dose of LY2484595 and had evaluable LY2484595 concentration data.</population>
          <units>Hours (h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="3.00" lower_limit="2.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Wilcoxon signed rank</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>0.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Area Under the Concentration-time Curve (AUC) of LY2484595</title>
        <description>The geometric least squares (LS) means of area under the concentration-time curve (AUC) from time zero extrapolated to infinity (AUC0-∞) of LY2484595 following administration of LY2484595 alone and with ketoconazole are reported. Least squares means were calculated from an analysis of variance (ANOVA) model with a fixed effect for treatment and a random effect for participant. The LS means for each treatment and the 90% confidence intervals (CI) for the difference in means were back transformed from the log scale to provide estimates of the geometric means and 90% CIs for the ratio of the geometric means (LY2484595 coadministered with ketoconazole and LY2484595 alone).</description>
        <time_frame>Part 2, Period 1, Day 1 through Day 8: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168 Hours Post Dose; Period 2, Day 5 through Day 15: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240 Hours Post Dose</time_frame>
        <population>Participants who received at least 1 dose of LY2484595 and had at least 3 consecutive plasma LY2484595 concentrations above the lower limit of quantification with at least 1 of these concentrations following the maximum observed plasma concentration (Cmax).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Period 1: 100 mg LY2484595</title>
            <description>Period 1:
LY2484595: 100 milligrams (mg), tablet, oral administration, single dose on Day 1 of Period 1
Washout period lasting ≥ 14 days
Period 2:
Ketoconazole: 400 mg, tablet, oral administration, once daily (QD) on Days 1 through 14 of Period 2
LY2484595: 100 mg, tablet, oral administration, single dose on Day 5 of Period 2</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Period 2: 100 mg LY2484595 + 400 mg Ketoconazole</title>
            <description>Period 1:
LY2484595: 100 milligrams (mg), tablet, oral administration, single dose on Day 1 of Period 1
Washout period lasting ≥ 14 days
Period 2:
Ketoconazole: 400 mg, tablet, oral administration, once daily (QD) on Days 1 through 14 of Period 2
LY2484595: 100 mg, tablet, oral administration, single dose on Day 5 of Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration-time Curve (AUC) of LY2484595</title>
          <description>The geometric least squares (LS) means of area under the concentration-time curve (AUC) from time zero extrapolated to infinity (AUC0-∞) of LY2484595 following administration of LY2484595 alone and with ketoconazole are reported. Least squares means were calculated from an analysis of variance (ANOVA) model with a fixed effect for treatment and a random effect for participant. The LS means for each treatment and the 90% confidence intervals (CI) for the difference in means were back transformed from the log scale to provide estimates of the geometric means and 90% CIs for the ratio of the geometric means (LY2484595 coadministered with ketoconazole and LY2484595 alone).</description>
          <population>Participants who received at least 1 dose of LY2484595 and had at least 3 consecutive plasma LY2484595 concentrations above the lower limit of quantification with at least 1 of these concentrations following the maximum observed plasma concentration (Cmax).</population>
          <units>Nanograms * hours per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5265" lower_limit="4106" upper_limit="6751"/>
                    <measurement group_id="O2" value="12471" lower_limit="9422" upper_limit="16508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Up to 12 participants were enrolled in order for 8 to complete the study. The estimated variability in area under the concentration-time curve (AUC) was 20% coefficient of variation following a single dose of 100 mg LY2484595. Assuming that 70% of the total variability is contributed by intra-participant variability, a sample size of 8 participants provides a precision of ~15% for the geometric means ratio in AUC and Cmax of LY2484595 + ketoconazole to LY2484595 alone in log scale.</non_inferiority_desc>
            <param_type>Ratio of Geometric LS means</param_type>
            <param_value>2.37</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.77</ci_lower_limit>
            <ci_upper_limit>3.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics: Change From Baseline to Day 21 in Cholesteryl Ester Transfer Protein (CETP) Activity</title>
        <time_frame>Day 1 (Baseline) and Day 21</time_frame>
        <population>Participants who received at least 1 dose of LY2484595 or placebo and had evaluable pharmacodynamic (CETP) data.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 (Cohorts A Through D): Placebo</title>
            <description>Placebo: tablets, oral administration, once daily (QD) on Days 1 through 14 of Period 1 (all cohorts) and Days 1 through 14 of Period 2 (Cohort A only)</description>
          </group>
          <group group_id="O2">
            <title>Part 1, Period 1 (Cohort A): 100 mg LY2484595</title>
            <description>LY2484595: 100 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14 of Period 1</description>
          </group>
          <group group_id="O3">
            <title>Part 1 (Cohort B): 300 mg LY2484595</title>
            <description>LY2484595: 300 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14</description>
          </group>
          <group group_id="O4">
            <title>Part 1 (Cohort C): 600 mg LY2484595</title>
            <description>LY2484595: 600 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14</description>
          </group>
          <group group_id="O5">
            <title>Part 1 (Cohort D): 1200 mg LY2484595</title>
            <description>LY2484595: 1200 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14</description>
          </group>
          <group group_id="O6">
            <title>Part 1, Period 2 (Cohort A): 1800 mg LY2484595</title>
            <description>LY2484595: 1800 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14 of Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Change From Baseline to Day 21 in Cholesteryl Ester Transfer Protein (CETP) Activity</title>
          <population>Participants who received at least 1 dose of LY2484595 or placebo and had evaluable pharmacodynamic (CETP) data.</population>
          <units>Picomoles per milliliters per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="6.9"/>
                    <measurement group_id="O2" value="-0.4" spread="3.1"/>
                    <measurement group_id="O3" value="-0.4" spread="6.3"/>
                    <measurement group_id="O4" value="-9.1" spread="8.8"/>
                    <measurement group_id="O5" value="-9.5" spread="5.0"/>
                    <measurement group_id="O6" value="-12.9" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacodynamics: Change From Baseline to Day 21 in High-density Lipoprotein Cholesterol (HDL-C), Low-density Lipoprotein Cholesterol (LDL-C), and Triglycerides (TG)</title>
        <time_frame>Day 1 (Baseline) and Day 21</time_frame>
        <population>Participants who received at least 1 dose of LY2484595 or placebo during Period 1 and had evaluable pharmacodynamic (HDL-C, LDL-C, TG) data.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1, Period 1 (Cohorts A Through D): Placebo</title>
            <description>Placebo: tablets, oral administration, once daily (QD) on Days 1 through 14 of Period 1 (all cohorts)</description>
          </group>
          <group group_id="O2">
            <title>Part 1, Period 1 (Cohort A): 100 mg LY2484595</title>
            <description>LY2484595: 100 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14 of Period 1</description>
          </group>
          <group group_id="O3">
            <title>Part 1 (Cohort B): 300 mg LY2484595</title>
            <description>LY2484595: 300 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14</description>
          </group>
          <group group_id="O4">
            <title>Part 1 (Cohort C): 600 mg LY2484595</title>
            <description>LY2484595: 600 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14</description>
          </group>
          <group group_id="O5">
            <title>Part 1 (Cohort D): 1200 mg LY2484595</title>
            <description>LY2484595: 1200 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics: Change From Baseline to Day 21 in High-density Lipoprotein Cholesterol (HDL-C), Low-density Lipoprotein Cholesterol (LDL-C), and Triglycerides (TG)</title>
          <population>Participants who received at least 1 dose of LY2484595 or placebo during Period 1 and had evaluable pharmacodynamic (HDL-C, LDL-C, TG) data.</population>
          <units>Millimoles per liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.17"/>
                    <measurement group_id="O2" value="0.35" spread="0.22"/>
                    <measurement group_id="O3" value="0.49" spread="0.31"/>
                    <measurement group_id="O4" value="0.77" spread="0.49"/>
                    <measurement group_id="O5" value="0.80" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.74"/>
                    <measurement group_id="O2" value="-0.16" spread="0.31"/>
                    <measurement group_id="O3" value="-0.48" spread="0.55"/>
                    <measurement group_id="O4" value="-1.15" spread="0.93"/>
                    <measurement group_id="O5" value="-1.01" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.87"/>
                    <measurement group_id="O2" value="0.55" spread="0.81"/>
                    <measurement group_id="O3" value="0.44" spread="0.61"/>
                    <measurement group_id="O4" value="0.26" spread="0.38"/>
                    <measurement group_id="O5" value="0.52" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of LY2484595</title>
        <description>The maximum observed plasma concentrations (Cmax) of LY2484595 after a single dose and after once daily (QD) dosing for 14 consecutive days are reported.</description>
        <time_frame>Part 1, Periods 1 and 2, Day 1: Predose, 1, 2, 3, 4, 6, 8, 12, and 24 Hours Postdose; Day 14 through Day 21: Predose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 168 Hours Post Dose</time_frame>
        <population>Participants who received at least 1 dose of LY2484595 and had evaluable LY2484595 concentration data.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1, Period 1 (Cohort A): 100 mg LY2484595</title>
            <description>LY2484595: 100 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14 of Period 1</description>
          </group>
          <group group_id="O2">
            <title>Part 1 (Cohort B): 300 mg LY2484595</title>
            <description>LY2484595: 300 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14</description>
          </group>
          <group group_id="O3">
            <title>Part 1 (Cohort C): 600 mg LY2484595</title>
            <description>LY2484595: 600 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14</description>
          </group>
          <group group_id="O4">
            <title>Part 1 (Cohort D): 1200 mg LY2484595</title>
            <description>LY2484595: 1200 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14</description>
          </group>
          <group group_id="O5">
            <title>Part 1, Period 2 (Cohort A): 1800 mg LY2484595</title>
            <description>LY2484595: 1800 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14 of Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of LY2484595</title>
          <description>The maximum observed plasma concentrations (Cmax) of LY2484595 after a single dose and after once daily (QD) dosing for 14 consecutive days are reported.</description>
          <population>Participants who received at least 1 dose of LY2484595 and had evaluable LY2484595 concentration data.</population>
          <units>Nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="628" spread="79"/>
                    <measurement group_id="O2" value="1990" spread="60"/>
                    <measurement group_id="O3" value="2720" spread="59"/>
                    <measurement group_id="O4" value="4450" spread="53"/>
                    <measurement group_id="O5" value="3580" spread="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="978" spread="41"/>
                    <measurement group_id="O2" value="1970" spread="37"/>
                    <measurement group_id="O3" value="4180" spread="42"/>
                    <measurement group_id="O4" value="5410" spread="48"/>
                    <measurement group_id="O5" value="5750" spread="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Time of Maximum Observed Plasma Concentration (Tmax) of LY2484595</title>
        <description>The times of maximum observed plasma concentrations (tmax) of LY2484595 after a single dose and after once daily (QD) dosing for 14 consecutive days are reported.</description>
        <time_frame>Part 1, Periods 1 and 2, Day 1: Predose, 1, 2, 3, 4, 6, 8, 12, and 24 Hours Postdose; Day 14 through Day 21: Predose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 168 Hours Post Dose</time_frame>
        <population>Participants who received at least 1 dose of study drug and had evaluable LY2484595 concentration data.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1, Period 1 (Cohort A): 100 mg LY2484595</title>
            <description>LY2484595: 100 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14 of Period 1</description>
          </group>
          <group group_id="O2">
            <title>Part 1 (Cohort B): 300 mg LY2484595</title>
            <description>LY2484595: 300 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14</description>
          </group>
          <group group_id="O3">
            <title>Part 1 (Cohort C): 600 mg LY2484595</title>
            <description>LY2484595: 600 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14</description>
          </group>
          <group group_id="O4">
            <title>Part 1 (Cohort D): 1200 mg LY2484595</title>
            <description>LY2484595: 1200 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14</description>
          </group>
          <group group_id="O5">
            <title>Part 1, Period 2 (Cohort A): 1800 mg LY2484595</title>
            <description>LY2484595: 1800 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14 of Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Time of Maximum Observed Plasma Concentration (Tmax) of LY2484595</title>
          <description>The times of maximum observed plasma concentrations (tmax) of LY2484595 after a single dose and after once daily (QD) dosing for 14 consecutive days are reported.</description>
          <population>Participants who received at least 1 dose of study drug and had evaluable LY2484595 concentration data.</population>
          <units>Hours (h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="2.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="3.00" lower_limit="1.00" upper_limit="8.00"/>
                    <measurement group_id="O3" value="3.00" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O4" value="2.00" lower_limit="1.00" upper_limit="8.00"/>
                    <measurement group_id="O5" value="2.00" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O3" value="2.50" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O4" value="2.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O5" value="3.00" lower_limit="1.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Area Under the Concentration-time Curve (AUC) of LY2484595</title>
        <description>Exposure to LY2484595 in terms of the area under the concentration-time curves (AUC) after a single dose and after once daily (QD) dosing for 14 consecutive days are reported.</description>
        <time_frame>Part 1, Periods 1 and 2, Day 1: Predose, 1, 2, 3, 4, 6, 8, 12, and 24 Hours Postdose; Day 14 through Day 21: Predose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 168 Hours Post Dose</time_frame>
        <population>All participants who received at least 1 dose of LY2484595 and had at least 3 consecutive plasma LY2484595 concentrations above the lower limit of quantification with at least 1 of these concentrations following the maximum observed plasma concentration (Cmax).</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1, Period 1 (Cohort A): 100 mg LY2484595</title>
            <description>LY2484595: 100 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14 of Period 1</description>
          </group>
          <group group_id="O2">
            <title>Part 1 (Cohort B): 300 mg LY2484595</title>
            <description>LY2484595: 300 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14</description>
          </group>
          <group group_id="O3">
            <title>Part 1 (Cohort C): 600 mg LY2484595</title>
            <description>LY2484595: 600 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14</description>
          </group>
          <group group_id="O4">
            <title>Part 1 (Cohort D): 1200 mg LY2484595</title>
            <description>LY2484595: 1200 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14</description>
          </group>
          <group group_id="O5">
            <title>Part 1, Period 2 (Cohort A): 1800 mg LY2484595</title>
            <description>LY284595: 1800 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14 of Period 2</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration-time Curve (AUC) of LY2484595</title>
          <description>Exposure to LY2484595 in terms of the area under the concentration-time curves (AUC) after a single dose and after once daily (QD) dosing for 14 consecutive days are reported.</description>
          <population>All participants who received at least 1 dose of LY2484595 and had at least 3 consecutive plasma LY2484595 concentrations above the lower limit of quantification with at least 1 of these concentrations following the maximum observed plasma concentration (Cmax).</population>
          <units>Nanograms * hour per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4780" spread="57"/>
                    <measurement group_id="O2" value="14500" spread="47"/>
                    <measurement group_id="O3" value="21300" spread="55"/>
                    <measurement group_id="O4" value="36300" spread="46"/>
                    <measurement group_id="O5" value="31300" spread="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8110" spread="30"/>
                    <measurement group_id="O2" value="17900" spread="27"/>
                    <measurement group_id="O3" value="36200" spread="38"/>
                    <measurement group_id="O4" value="46900" spread="43"/>
                    <measurement group_id="O5" value="56600" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All randomized participants who received at least 1 dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part 1 (Cohorts A Through D)</title>
          <description>Placebo: tablets, oral administration, once daily (QD) on Days 1 through 14 of Period 1 (all cohorts) and Days 1 through 14 of Period 2 (Cohort A only)</description>
        </group>
        <group group_id="E2">
          <title>Part 1, Period 1 (Cohort A)</title>
          <description>LY2484595: 100 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14 of Period 1</description>
        </group>
        <group group_id="E3">
          <title>Part 1, Period 2 (Cohort A)</title>
          <description>LY284595: 1800 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14 of Period 2</description>
        </group>
        <group group_id="E4">
          <title>Part 1 (Cohort B): 300 mg LY2484595</title>
          <description>LY2484595: 300 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14</description>
        </group>
        <group group_id="E5">
          <title>Part 1 (Cohort C): 600 mg LY2484595</title>
          <description>LY2484595: 600 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14</description>
        </group>
        <group group_id="E6">
          <title>Part 1 (Cohort D): 1200 mg LY2484595</title>
          <description>LY2484595: 1200 milligrams (mg), tablets, oral administration, once daily (QD) on Days 1 through 14</description>
        </group>
        <group group_id="E7">
          <title>Part 2, Period 1: 100 mg LY2484595</title>
          <description>Period 1:
LY2484595: 100 milligrams (mg), tablet, oral administration, single dose on Day 1 of Period 1
Washout period lasting ≥ 14 days
Period 2:
Ketoconazole: 400 mg, tablet, oral administration, once daily (QD) on Days 1 through 14 of Period 2
LY2484595: 100 mg, tablet, oral administration, single dose on Day 5 of Period 2</description>
        </group>
        <group group_id="E8">
          <title>Part 2, Period 2: 400 mg Ketoconazole</title>
          <description>Period 1:
LY2484595: 100 milligrams (mg), tablet, oral administration, single dose on Day 1 of Period 1
Washout period lasting ≥ 14 days
Period 2:
Ketoconazole: 400 mg, tablet, oral administration, once daily (QD) on Days 1 through 14 of Period 2
LY2484595: 100 mg, tablet, oral administration, single dose on Day 5 of Period 2</description>
        </group>
        <group group_id="E9">
          <title>Part 2, Period 2: 100 mg LY2484595 + 400 mg Ketoconazole</title>
          <description>Period 1:
LY2484595: 100 milligrams (mg), tablet, oral administration, single dose on Day 1 of Period 1
Washout period lasting ≥ 14 days
Period 2:
Ketoconazole: 400 mg, tablet, oral administration, once daily (QD) on Days 1 through 14 of Period 2
LY2484595: 100 mg, tablet, oral administration, single dose on Day 5 of Period 2</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="13" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oedema mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oral mucosal erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Feeling jittery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="16" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Muscle contractions involuntary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Capillary fragility</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

